Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.
IPO Year: 1990
Exchange: NASDAQ
Website: hologic.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2024 | $95.00 → $85.00 | Buy → Neutral | Citigroup |
| 6/27/2024 | $87.00 | Overweight | Stephens |
| 4/3/2024 | $80.00 → $95.00 | Neutral → Buy | Citigroup |
| 7/14/2023 | $95.00 | Hold → Buy | Needham |
| 12/7/2022 | $75.00 | Sector Perform | RBC Capital Mkts |
| 10/13/2022 | $75.00 | Buy | Mizuho |
| 7/20/2022 | $73.00 | Neutral | UBS |
| 7/20/2022 | $81.00 → $75.00 | Buy → Neutral | BofA Securities |
| 7/18/2022 | Buy → Neutral | BTIG Research | |
| 4/25/2022 | $75.00 | Overweight → Equal Weight | Wells Fargo |
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
– Revenue of $987.9 Million, GAAP Diluted EPS of $0.76 and Non-GAAP Diluted EPS of $1.01 – – Total Company Revenue Growth of 4.5%, or 4.2% in Constant Currency and 5.0% Organically ex. COVID-19 in Constant Currency – – Company Expects Strong Execution of its Broad-Based Growth Strategy in Fiscal 2025 – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 28, 2024. "We delivered strong fiscal 2024 results, reinforcing our track record of durable performance with another solid quarter of growth," said Steve MacMillan, Hologic's chairman, president, and chief executive officer. "Each year we grow stronger, leveraging our
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2024 on Monday, November 4, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 4567924. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at www.investors.ho
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Year Period – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal third quarter ended June 29, 2024. "In our third quarter of fiscal 2024, Hologic returns to top-line reported growth and once again exceeded the high-end of our guidance for both the top and bottom-line," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Our strong fiscal qua
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2024 on Monday, July 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 5372869. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at www.investors.holo
– Revenue of $1,017.8 Million, GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03; Revenue and Non-GAAP Diluted EPS Exceeded Guidance – – Total Company Organic Revenue Growth Excluding COVID-19 of 4.9% in Constant Currency; Against a 21.9% Prior Year Period Comparable – – Company Raises Full-Year Revenue Midpoint in Constant Currency and Raises EPS Guidance on Strong Margins – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal second quarter ended March 30, 2024. "At Hologic we continue to deliver, exceeding the high-end of our guidance for both the top and bottom-line, highlighting our durable growth even as we faced incredibly high
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2024 on Thursday, May 2, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 256-1007 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 7680382. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at www.investors.hol
– Revenue of $1,013.1 Million, GAAP Diluted EPS of $1.03, and Non-GAAP Diluted EPS of $0.98; All Exceed Guidance – – Total Company Organic Revenue Growth Excluding COVID-19 of 5.2% in Constant Currency Against Four Fewer Selling Days Compared to the Prior Year Period – – Company Increases Full-Year Revenue and EPS Guidance - Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 30, 2023. "We delivered strong revenue and profitability to start fiscal 2024, exceeding the high-end of our guidance for both the top-line and the bottom-line. Adjusting for the four fewer selling days in the quarter, we estimate our organic g
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2024 on Thursday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 5909239. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at https://inves
– Revenue of $945.3 Million, GAAP Diluted EPS of $0.37, and Non-GAAP Diluted EPS of $0.89 – – Total Company Organic Revenue Growth excluding COVID-19 of 16.7% in constant currency – – Expect Broad Based Strong Performance in Fiscal 2024 – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 30, 2023. "Hologic delivered remarkable fiscal 2023 results extending our track record of strong performance with another solid quarter of growth in our fourth quarter," said Steve MacMillan, the Company's chairman, president and chief executive officer. "Each one of our divisions grew double digits organically in the quarter an
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2023 on Thursday, November 9, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (866) 400-0049 (in the United States and Canada) or +1 (773) 305-6867 (for international callers) and referencing access code 1937661. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. A webcast replay will be available approximately two hours after the call ends. Hologic will provid
8-K - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
144 - HOLOGIC INC (0000859737) (Subject)
10-Q - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
SD - HOLOGIC INC (0000859737) (Filer)
8-K/A - HOLOGIC INC (0000859737) (Filer)
10-Q - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod
For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump
Hologic (NASDAQ:HOLX) has outperformed the market over the past 20 years by 6.31% on an annualized basis producing an average annual return of 14.81%. Currently, Hologic has a market capitalization of $18.13 billion. Buying $100 In HOLX: If an investor had bought $100 of HOLX stock 20 years ago, it would be worth $1,541.14 today based on a price of $77.69 for HOLX at the time of writing. Hologic's Performance Over Last 20 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and revie
Evercore ISI Group analyst Vijay Kumar maintains Hologic (NASDAQ:HOLX) with a In-Line and lowers the price target from $78 to $76.
Hologic's (NYSE:HOLX) short percent of float has fallen 8.59% since its last report. The company recently reported that it has 4.64 million shares sold short, which is 2.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.77 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is im
Stephens initiated coverage on Hologic Inc (NASDAQ:HOLX), citing it as a major player in women’s health, known for its consistent revenue growth, strong free cash flow, and attractive profit margins, is well-positioned in the molecular diagnostics sector post-COVID. Stephens analyst writes, “Hologic is a leader in women’s health with a portfolio of products that have become the gold standard for care. Hologic emerged from the pandemic with new growth drivers, a scaled installed base, and a stronger balance sheet.” The analyst says Hologic is well-positioned to execute on near-term targets and fuel long-term growth. A change to cervical cancer screening guidelines can potentially cause
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital analyst Keith Tapper initiated coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with an Outperform rating and announced a price target of $31. ACADIA Pharmaceuticals shares fell 0.6% to close at $15.50 on Wednesday. See how other analysts view this stock. Mizuho analyst Wei Fang initiated coverage on Grab Holdings Limited (NASDAQ:GRAB) with an Outperform rating and announced a price target of $5. Grab shares fell 0.3% to close at $3.51 on Wednesday. See how other analy
Throughout the last three months, 7 analysts have evaluated Hologic (NASDAQ:HOLX), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 1 0 0 0 3M Ago 2 0 1 0 0 Analysts have set 12-month price targets for Hologic, revealing an average target of $89.43, a high estimate of $95.00, and a low estimate of $78.00. This upwa
Stephens & Co. analyst Mason Carrico initiates coverage on Hologic (NASDAQ:HOLX) with a Overweight rating and announces Price Target of $87.
https://www.fda.gov/medical-devices/medical-device-recalls/hologic-inc-recalls-biozorb-marker-due-complications-implanted-devices
https://www.fda.gov/medical-devices/medical-device-recalls/hologic-inc-recalls-biozorb-marker-due-complications-implanted-devices
Argus Research analyst David Toung maintains Hologic (NASDAQ:HOLX) with a Buy and raises the price target from $89 to $95.
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company will present at the following upcoming investor conferences: 2024 Stephens Annual Investment Conference in Nashville, TN on Thursday, November 21st, at 10 a.m. Central Time (CT). 7th Annual Evercore ISI HealthCONx Conference in Coral Gables, FL on Tuesday, December 3rd, at 2:10 p.m. Eastern Time (ET). Citi's 2024 Global Healthcare Conference in Miami, FL on Wednesday, December 4th, at 8:45 a.m. ET. Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic's website at http://investors.hologic.com. The webcasts will be available for 30 days following each event. Abou
– Revenue of $987.9 Million, GAAP Diluted EPS of $0.76 and Non-GAAP Diluted EPS of $1.01 – – Total Company Revenue Growth of 4.5%, or 4.2% in Constant Currency and 5.0% Organically ex. COVID-19 in Constant Currency – – Company Expects Strong Execution of its Broad-Based Growth Strategy in Fiscal 2025 – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 28, 2024. "We delivered strong fiscal 2024 results, reinforcing our track record of durable performance with another solid quarter of growth," said Steve MacMillan, Hologic's chairman, president, and chief executive officer. "Each year we grow stronger, leveraging our
Hologic, Inc. (NASDAQ:HOLX), a global champion of women's health, today announced that it has signed a definitive agreement to acquire Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women's health for approximately $350 million, subject to working capital and other customary closing adjustments. Gynesonics, which is based in Redwood City, California, develops and sells the Sonata® System, a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. The Sonata System combines real-t
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2024 on Monday, November 4, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 4567924. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at www.investors.ho
Company Kicks Off October by Ringing Nasdaq Opening Bell, Releasing Educational Resources for Women Hologic, Inc. (NASDAQ:HOLX), a global leader in women's health, will kick off Breast Cancer Awareness Month by ringing the Nasdaq opening bell for the 18th year. As part of this annual tradition, Hologic is launching a comprehensive patient education campaign to bust common myths about breast cancer, mammograms and breast density. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241001856705/en/Breast Cancer Awareness Month (Graphic: Business Wire) "As a leading women's health organization, we are committed to supporting women at ev
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5th, at 12:20 p.m. Eastern Time. The fire-side chat presentation will be webcast live and may be accessed through a link on the investors section of Hologic's website at http://investors.hologic.com. The webcast will be available for 30 days following the event. About Hologic, Inc. Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com. SOURCE: Hologic, Inc.
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Year Period – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal third quarter ended June 29, 2024. "In our third quarter of fiscal 2024, Hologic returns to top-line reported growth and once again exceeded the high-end of our guidance for both the top and bottom-line," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Our strong fiscal qua
Hologic, Inc. (NASDAQ:HOLX), a global leader in women's health, has completed its previously announced acquisition of Endomagnetics Ltd (Endomag), a privately held UK-based developer of breast cancer surgery technologies, for approximately $310 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725351417/en/Endomagnetics breast cancer surgery technologies (Photo: Business Wire) "We are thrilled to complete the acquisition of Endomag and are looking forward to working with our new colleagues to increase access to their innovative technologies, which complement and diversify our expanding interventional breast health portf
New Survey Reveals Women Struggle to Prioritize Their Health Millions of women in the United States have missed screenings for serious, often life-threatening conditions, according to a new survey released today by women's health innovator Hologic, Inc. (NASDAQ:HOLX). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709118503/en/Hologic Global Women's Health Index - United States Data Report (Graphic: Business Wire) The nationally representative study, commissioned by Hologic and conducted by Gallup, reveals a vast "Screening Action Gap." Although women overwhelmingly say regular health screenings are important, an estimated
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2024 on Monday, July 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 5372869. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at www.investors.holo
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
BERWYN, Pa., Feb. 11, 2021 /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced that its Board of Directors has appointed Karleen Oberton as a new director of the Company. Ms. Oberton serves as Chief Financial Officer of Hologic, Inc. (NASDAQ: HOLX), an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment systems. "We are pleased to welcome Karleen to AMETEK as a member of our Board of Directors," commented David A. Zapico, AMETEK Chairman and Chief Executive Officer. "Karleen is a skilled business executive with more than 30 years of experience in public accounting, biotechnology and medical device m
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 26, 2020. The Company expects to report total revenues of approximately $1,609.8 million, an increase of 89.3% compared to the prior year period, or 86.5% in constant currency. These preliminary results compare to the Company’s most recent guidance range of $1,350 to $1,425 million, which was provided on November 4, 2020. “Hologic’s strong momentum continued in the first quarter of fiscal 2021 as organic revenue more than doubled, well ahead of our prior expectations,” said Steve MacMillan, the Company’s Chairman, President and
Citigroup downgraded Hologic from Buy to Neutral and set a new price target of $85.00 from $95.00 previously
Stephens initiated coverage of Hologic with a rating of Overweight and set a new price target of $87.00
Citigroup upgraded Hologic from Neutral to Buy and set a new price target of $95.00 from $80.00 previously
Needham upgraded Hologic from Hold to Buy and set a new price target of $95.00
RBC Capital Mkts initiated coverage of Hologic with a rating of Sector Perform and set a new price target of $75.00
Mizuho initiated coverage of Hologic with a rating of Buy and set a new price target of $75.00
UBS initiated coverage of Hologic with a rating of Neutral and set a new price target of $73.00
BofA Securities downgraded Hologic from Buy to Neutral and set a new price target of $75.00 from $81.00 previously
BTIG Research downgraded Hologic from Buy to Neutral
Wells Fargo downgraded Hologic from Overweight to Equal Weight and set a new price target of $75.00